ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
10 September 2020 - 9:08AM
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology
and oncology focused biopharmaceutical company developing
innovative treatments to transform the lives of patients, today
announced its presentation at the H.C. Wainwright 22nd Annual
Global Investment Conference. Dr Carl Firth, Chief Executive
Officer is scheduled to make a company presentation on 16 September
2020 at 9:00am EDT. The virtual conference will be held from 14-16
September 2020.
The presentation deck used at the conference will be available
in the Investors section of ASLAN’s website at www.aslanpharma.com
following the event.
Media and IR contacts
Emma ThompsonSpurwing CommunicationsTel: +65 6751
2021Email: ASLAN@spurwingcomms.com |
Robert UhlWestwicke PartnersTel: +1 858 356 5932
Email: robert.uhl@westwicke.com |
About ASLAN Pharmaceuticals ASLAN
Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology and
oncology focused biopharmaceutical company developing innovative
treatments to transform the lives of patients. Led by a senior
management team with extensive experience in global development and
commercialisation, ASLAN has a clinical portfolio comprised of a
first in class monoclonal therapy, ASLAN004, that is being
developed in atopic dermatitis and other immunology indications,
and a small molecule inhibitor targeting oncology. ASLAN’s partners
include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL.
For additional information please visit www.aslanpharma.com.
Forward looking statements
This release and the accompanying financial information, if any,
contains forward-looking statements. These statements are based on
the current beliefs and expectations of the management of ASLAN
Pharmaceuticals Limited and/or its affiliates (the "Company").
These forward-looking statements may include, but are not limited
to, statements regarding the Company’s business strategy, the
Company’s plans to develop and commercialise its product
candidates, the safety and efficacy of the Company’s product
candidates, the Company’s plans and expected timing with respect to
regulatory filings and approvals, and the size and growth potential
of the markets for the Company’s product candidates. The Company’s
estimates, projections and other forward-looking statements are
based on management's current assumptions and expectations of
future events and trends, which affect or may affect the Company’s
business, strategy, operations or financial performance, and
inherently involve significant known and unknown risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation the risk factors described in the
Company’s U.S. Securities and Exchange Commission filings and
reports (Commission File No. 001-38475), including the Company’s
Form 20-F filed with the U.S. Securities and Exchange Commission
(the “SEC”) on April 16, 2020.
All statements other than statements of historical fact are
forward-looking statements. The words “believe,” “may,” “might,”
“could,” “will,” “aim,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plan,” or the negative of those terms, and
similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. Estimates, projections and other
forward-looking statements speak only as of the date they were
made, and, except to the extent required by law, the Company
undertakes no obligation to update or review any estimate,
projection or forward-looking statement.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024